Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Even some of the S&P 500's (SNPINDEX: ^GSPC) seemingly safe dividend stocks have been upended, even if only because so many ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...

Pfizer’s Padcev plus Keytruda combo shows significant survival gains in muscle‑invasive bladder cancer and could become ...

Cowboys owner Jerry Jones revealed he quietly battled stage 4 melanoma for over a decade, crediting experimental ...